Lancet Neurology: Satralizumab Treats Psycolititis Spectrum Disorders (NMOSD), Safe and Effective
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Chugai Pharmaceuticals Co., Ltdrecently announced that the results of Satralizumab's Global Phase III SakuraStar Study (NCT02073279) were released on April 22 in LancetySatralizumab is a humanized antibody against IL6 receptors and is being developed to treat psyroidal spinal cord inflammation disorder (NMOSD)Phase III studies examined the effectiveness and safety of Satralizumab single-drug treatment of NMOSDNMOSD is a rare autoimmune disease of the central nervous system in which the immune system attacks the optic nerve and spinal cord, causing vision loss and paralysis"The long-term efficacy of Satralizumab single medicine underscores the important role of IL-6 inhibition in the treatment of NMOSD," said DrOsamu Okuda, President and Chief Operating Officer of ChugaiIn the SakuraStar study, Satralizumab significantly reduced the risk of recurrence in the population as a wholeImportantly, patients treated with Satralizumab had no recurrence at 48, 96 and 144 weeks, with 76.1%, 72.1% and 62.8% of non-recurrence rates, respectively, compared with 61.9%, 51.2% and 34.1% of patients in the placebo groupThe proportion of severe adverse events was similar between Satralizumab and placebo treatment groups, and the most common adverse events in the Satralizumab group were urinary tract infections and upper respiratory tract infections
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
